ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 155 filers reported holding ASCENDIS PHARMA A/S in Q3 2020. The put-call ratio across all filers is 0.38 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $1,229,000 | +1517.1% | 13,190 | +2135.6% | 0.00% | – |
Q1 2021 | $76,000 | -25.5% | 590 | 0.0% | 0.00% | – |
Q4 2020 | $102,000 | +6.2% | 590 | 0.0% | 0.00% | – |
Q3 2020 | $96,000 | +15.7% | 590 | 0.0% | 0.00% | – |
Q2 2020 | $83,000 | +27.7% | 590 | 0.0% | 0.00% | – |
Q1 2020 | $65,000 | -77.0% | 590 | -70.8% | 0.00% | – |
Q4 2019 | $282,000 | +41.7% | 2,024 | -2.1% | 0.00% | – |
Q3 2019 | $199,000 | -14.6% | 2,067 | +2.1% | 0.00% | – |
Q2 2019 | $233,000 | -41.8% | 2,024 | -40.4% | 0.00% | – |
Q1 2019 | $400,000 | +93.2% | 3,396 | +2.7% | 0.00% | – |
Q4 2018 | $207,000 | -11.5% | 3,308 | 0.0% | 0.00% | – |
Q3 2018 | $234,000 | +6.4% | 3,308 | 0.0% | 0.00% | – |
Q2 2018 | $220,000 | +1.9% | 3,308 | 0.0% | 0.00% | – |
Q1 2018 | $216,000 | +31.7% | 3,308 | -19.3% | 0.00% | – |
Q4 2017 | $164,000 | +10.1% | 4,098 | 0.0% | 0.00% | – |
Q3 2017 | $149,000 | +18.3% | 4,098 | -9.6% | 0.00% | – |
Q2 2017 | $126,000 | +125.0% | 4,535 | +127.4% | 0.00% | – |
Q1 2017 | $56,000 | – | 1,994 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |